Differences in the Evolution of Clinical, Biochemical, and Hematological Indicators in Hospitalized Patients with COVID-19 According to Their Vaccination Scheme: A Cohort Study in One of the World’s Highest Hospital Mortality Populations.

Differences in the Evolution of Clinical, Biochemical, and Hematological Indicators in Hospitalized Patients with COVID-19 According to Their Vaccination Scheme: A Cohort Study in One of the World’s Highest Hospital Mortality Populations.

Publication date: Jan 11, 2024

COVID-19 vaccines primarily prevent severe illnesses or hospitalization, but there is limited data on their impact during hospitalization for seriously ill patients. In a Mexican cohort with high COVID-19 mortality, a study assessed vaccination’s effects. From 2021 to 2022, 462 patients with 4455 hospital days were analyzed. The generalized multivariate linear mixed model (GENLINMIXED) with binary logistic regression link, survival analysis and ROC curves were used to identify risk factors for death. The results showed that the vaccinated individuals were almost half as likely to die (adRR = 0. 54, 95% CI = 0. 30-0. 97, p = 0. 041). When stratifying by vaccine, the Pfizer group (BNT162b2) had a 2. 4-times lower risk of death (adRR = 0. 41, 95% CI = 0. 2-0. 8, p = 0. 008), while the AstraZeneca group (ChAdOx1-S) group did not significantly differ from the non-vaccinated (adRR = 1. 04, 95% CI = 0. 5-2. 3, p = 0. 915). The Pfizer group exhibited a higher survival, the unvaccinated showed increasing mortality, and the AstraZeneca group remained intermediate (p = 0. 003, multigroup log-rank test). Additionally, BNT162b2-vaccinated individuals had lower values for markers, such as ferritin and D-dimer. Biochemical and hematological indicators suggested a protective effect of both types of vaccines, possibly linked to higher lymphocyte counts and lower platelet-to-lymphocyte ratio (PLR). It is imperative to highlight that these results reinforce the efficacy of COVID-19 vaccines. However, further studies are warranted for a comprehensive understanding of these findings.

Open Access PDF

Concepts Keywords
Basel cohort study
Hospitalization COVID-19
Mexican diagnostic markers
hospitalized patients
mortality
vaccination scheme

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
drug DRUGBANK Saquinavir
disease MESH death
disease VO vaccinated
disease VO vaccine
disease VO unvaccinated
drug DRUGBANK Coenzyme M
disease VO USA
disease MESH infections
disease IDO country
disease VO Ad26.COV2.S
disease VO population
drug DRUGBANK Oxygen
disease MESH emergency
disease MESH Pneumonia
disease IDO process
disease IDO history
disease VO dose
disease IDO blood
disease MESH inflammation
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Creatinine
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK L-Alanine
drug DRUGBANK Rasagiline
drug DRUGBANK Prothrombin
drug DRUGBANK Acetaminophen
disease VO effective
disease VO ANOVA
disease VO time
disease VO vaccine dose
disease IDO infection

Original Article

(Visited 1 times, 1 visits today)